Portola Pharmaceuticals, Inc. Interest Expense
Portola Pharmaceuticals, Inc. reported Interest Expense of $8.15 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2020-05-11
- Portola Pharmaceuticals, Inc. interest expense for the quarter ending 2020-03-31 was $8.15M, a 25.71% increase year-over-year.
- Portola Pharmaceuticals, Inc. interest expense for the quarter ending 2019-12-31 was $8.27M, a 35.67% increase year-over-year.
- Portola Pharmaceuticals, Inc. interest expense for the quarter ending 2019-09-30 was $8.00M, a 34.26% increase year-over-year.
- Portola Pharmaceuticals, Inc. interest expense for the quarter ending 2019-06-30 was $8.54M, a 108.04% increase year-over-year.
- Portola Pharmaceuticals, Inc. interest expense for fiscal 2019 was $31.29M, a 66.97% increase from fiscal 2018.
- Portola Pharmaceuticals, Inc. interest expense for fiscal 2018 was $18.74M, a 61.51% increase from fiscal 2017.
- Portola Pharmaceuticals, Inc. interest expense for fiscal 2017 was $11.60M, a 18921.31% increase from fiscal 2016.
- Portola Pharmaceuticals, Inc. interest expense for fiscal 2016 was $61.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $8.15M 10-Q · filed 2020-05-11 | $16.42M derived: sum of 2 quarters · filed 2020-05-11 | $24.42M derived: sum of 3 quarters · filed 2020-05-11 | $32.96M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $16.27M derived: sum of 2 quarters · filed 2020-02-28 | $24.81M derived: sum of 3 quarters · filed 2020-02-28 | $31.29M 10-K · filed 2020-02-28 |
| 2019-09-30 | $8.00M 10-Q · filed 2019-11-05 | $16.54M derived: sum of 2 quarters · filed 2019-11-05 | $23.02M 10-Q · filed 2019-11-05 | $29.11M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-06-30 | $8.54M 10-Q · filed 2019-08-07 | $15.02M 10-Q · filed 2019-08-07 | $21.12M derived: sum of 3 quarters · filed 2020-05-11 | $27.07M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-03-31 | $6.48M 10-Q · filed 2020-05-11 | $12.58M derived: sum of 2 quarters · filed 2020-05-11 | $18.54M derived: sum of 3 quarters · filed 2020-05-11 | $22.64M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $12.05M derived: sum of 2 quarters · filed 2020-02-28 | $16.16M derived: sum of 3 quarters · filed 2020-02-28 | $18.74M 10-K · filed 2020-02-28 |
| 2018-09-30 | $5.96M 10-Q · filed 2019-11-05 | $10.06M derived: sum of 2 quarters · filed 2019-11-05 | $12.64M 10-Q · filed 2019-11-05 | $16.00M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $4.10M 10-Q · filed 2019-08-07 | $6.68M 10-Q · filed 2019-08-07 | $10.04M derived: sum of 3 quarters · filed 2020-02-28 | $13.19M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $2.58M 10-Q · filed 2019-05-08 | $5.94M derived: sum of 2 quarters · filed 2020-02-28 | $9.09M derived: sum of 3 quarters · filed 2020-02-28 | $12.54M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $6.51M derived: sum of 2 quarters · filed 2020-02-28 | $9.96M derived: sum of 3 quarters · filed 2020-02-28 | $11.60M 10-K · filed 2020-02-28 |
| 2017-09-30 | $3.15M 10-Q · filed 2018-11-07 | $6.60M derived: sum of 2 quarters · filed 2018-11-07 | $8.24M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $3.46M 10-Q · filed 2018-08-09 | $5.09M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $1.64M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $61.00K 10-K · filed 2019-03-01 | |||
| 2011-12-31 | $21.00K 10-K · filed 2014-03-03 |